Rilonacept Medicine 03 December 2024 Extended indication Treatment of idiopathic pericarditis. Therapeutic value No estimate possible yet Total cost Registration phase No registration expected Product Active substance Rilonacept Domain Cardiovascular diseases Reason of inclusion Biosimilar BS Main indication Other medication for cardiovascular diseases Extended indication Treatment of idiopathic pericarditis. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Portfolio holder Mechanism of action Unknown Route of administration Unknown Therapeutical formulation Unknown Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date October 2024 Expected Registration July 2025 Orphan drug Yes Registration phase No registration expected Reimbursement Medicine sluice Additional remarks Teruggetrokken in februari 2025. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks